News

Five pharma markers are recalling the diabetes medication due to the presence of a carcinogenic ingredient.

HHS says supply could run out by the end of this month.

As the U.S. begins reopening, potentially sparking a “second wave” of COVID-19 cases, hospitals and health systems will need to continue operating in a state of high-stress readiness.

Nothing can bring a healthcare system to its knees quite like a pandemic. What COVID-19 is leaving in its wake is a new respect for numbers - for accurate data that can predict new threats, track current ones and trigger an avalanche of innovative responses.

During the American Society of Clinical Oncology 2020 Annual Meeting, Flatiron Health, Foundation Medicine, and Genentech presented plans for the Prospective Clinico-Genomic study (PCG), a low-interventional pilot that will use a technology-enabled prospective data collection platform to simplify data collection for patients with lung cancer being treated through clinical trials.

The agency welcomes another option for serious bacterial infections.

Survey of over 1,000 people shows that use of telehealth has tripled.

As COVID-19 has spread around the world, data has shown that those with weakened immune systems are among the most susceptible to severe illness from the virus.

Amid considerable uncertainty in healthcare, quality care coordination is largely within your own control and can make an immensely positive impact on those you serve.

Dwindling reliance on primary care physicians is burdening healthcare system and limiting care resources.

The Institute for Clinical and Economic Review (ICER) found siponimod has benefits for patients with active secondary progressive multiple sclerosis, but its benefits were in line with other therapies in a crowded marketplace.

Much remains unknown about how precisely multiple sclerosis occurs and advances in patients, but a growing body of research is helping scientists develop new ways to slow, and potentially stop, disease progression.

Proving therapeutic equivalence is a major hurdle.

Developing a biosimilar can be more challenging than developing the innovator product because of the need to match the attributes of a highly complex molecules.

Hotspots can be predicted by identifying areas with a large percentage of residents with chronic conditions.

For those of us who spend our lives and careers fighting to improve care for individuals with the most significant medical, social and behavioral health needs, a study that found disappointing results from a well-regarded model will not deter us, but only reinforce the power and necessity of our endeavor.

Kathi Mooney, Ph.D., RN, FAAN, interim senior director of population sciences at the Huntsman Cancer Institute in Salt Lake City, discusses hospital-at-home programs and how they are common in countries with single-payer systems and include patients with conditions ranging from cellulitis to heart failure. The benefits include the familiarity of home surroundings, avoidance of hospital-acquired infection, and less de-conditioning from being in a hospital bed.

Anesthesia practices see major financial hit as physician anesthesiologists pivot during COVID-19 to treat patients in critical care and ICUs, ASA survey highlights.

Brilinta is already approved to prevent atherothrombotic events in ASC.

Immediately after the FDA said it found elevated levels of the carcinogenic ingredient N-nitrosodimethylamine (NDMA) in certain extended release (ER) metformin products, the first 2 major recalls are underway.

Jeffrey Skolnik, MD, vice president, clinical development of Inovio Pharmaceuticals Inc Discusses Glioblastoma Treatment in ASCO interview.

Adrian Kilcoyne MD MBA MPH, vice president, US Medical Affairs and HEOR, oncology, AstraZeneca, discusses a paradigm shift in lung cancer treatment due to the overwhelming efficacy of the EGFR-TKI treatment.

A digital-first strategy is a way to navigate through the COVID-19 storm.

Despite heroic efforts by hospitals across the country, the healthcare supply chain has struggled in the fight against COVID-19.

Tagrisso, the targeted therapy made by AstraZeneca, could become the treatment of choice for the majority of lung cancer patients with mutations in a certain gene who are treated after surgery, based on findings presented this past weekend at the American Society of Clinical Oncology annual meeting.

Keytruda, the immunotherapy with more than 20 indications in both blood and solid tumor cancers, doubled rates of progression-free survival for certain patients with metastatic colorectal cancer, according to results presented Sunday at the American Society of Clinical Oncology annual meeting.

During the American Society of Clinical Oncology 2020 Annual Meeting, Flatiron Health, Foundation Medicine, and Genentech will be presenting plans for the Prospective Clinico-Genomic study (PCG), a low-interventional pilot that will use a technology-enabled prospective data collection platform to simplify data collection for patients with lung cancer being treated through clinical trials. The idea is collect blood samples using Foundation Medicine’s liquid biopsy assay and analyze the results through Flatiron’s platform, to see if genomic changes can be detected over the course of cancer treatment. Bobby Green, MD, chief medical officer for Flatiron Health, spoke with Managed Healthcare Executive®.